Article
Discovery of fluorobenzimidazole HCV NS5A inhibitors.
Bioorganic & medicinal chemistry letters - 15 Nov 2016
Randolph John T, Flentge Charles A, Donner Pamela, Rockway Todd W, Patel Sachin V, Nelson Lissa, Hutchinson Douglas K, Mondal Rubina, Mistry Neeta, Reisch Thomas, Dekhtyar Tatyana, Krishnan Preethi, Pilot-Matias Tami, Stolarik Deanne F, Beno David W A, Wagner Rolf, Maring Clarence, Kati Warren M
Abstract excerpt
Research toward a next-generation HCV NS5A inhibitor has identified fluorobenzimidazole analogs that demonstrate potent, broad-genotype in vitro activity against HCV genotypes 1-6 replicons as well as HCV NS5A variants that are orders of magnitude less susceptible to inhibition by first-generation NS5A inhibitors in comparison to wild-type replicons. The fluorobenzimidazole inhibitors have improved...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.